Sprint Bioscience Liabilities 2024

Sprint Bioscience Aktienanalyse

What does Sprint Bioscience do?

The Swedish company Sprint Bioscience AB is an innovative developer of drugs targeted for use in cancer. The company was founded in Stockholm in 2009 and has since worked with a strong focus on molecular research. Sprint Bioscience is a biotechnology company with the goal of developing drugs for various types of cancer. The company's focus is on so-called "trickster molecules" that can prevent tumor cells from taking up nutrients, ultimately leading to their death. The innovative business model of Sprint Bioscience is that they focus on the discovery and development of molecules, which they then sell to larger pharmaceutical companies that further develop and bring them to market. Sprint Bioscience has a wide range of molecular tools that allow for the identification, development, and optimization of cancer therapy drugs. The company aims to accelerate the discovery of new drugs in the field of oncology. Sprint Bioscience is divided into two business areas: discovery, which specializes in the identification and optimization of drugs for use in cancer, and development, which focuses on the preclinical development of drugs that are later further developed by larger pharmaceutical companies. The most well-known product of Sprint Bioscience is the molecule "SB-11285", a novel cancer therapeutic specifically developed for ovarian cancer. The molecule is intended to help destroy cancer cells by disrupting their cellular metabolism and depriving them of their energy source. Sprint Bioscience has also formed partnerships with other companies to exchange technologies and expertise. For example, there is a collaboration with Bayer to develop new oncology drugs. Overall, Sprint Bioscience has undergone significant development in recent years. The company has built strong expertise in the field of molecular research and effectively implemented its business model. Sprint Bioscience presents itself as a promising player in the biotechnology industry and has the potential to achieve further significant progress in the coming years. Sprint Bioscience ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Sprint Bioscience's Liabilities

Sprint Bioscience's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Sprint Bioscience's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Sprint Bioscience's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Sprint Bioscience's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Sprint Bioscience’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Sprint Bioscience stock

What is the level of liabilities of Sprint Bioscience this year?

Sprint Bioscience has a debt balance of 34.6 M SEK this year.

What were the liabilities of Sprint Bioscience compared to the previous year?

The liabilities of Sprint Bioscience have increased by 274.73% increased compared to the previous year.

What are the consequences of high debt for investors of Sprint Bioscience?

High liabilities can pose a risk for investors of Sprint Bioscience, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Sprint Bioscience?

Low liabilities mean that Sprint Bioscience has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Sprint Bioscience affect the company?

An increase in liabilities of Sprint Bioscience can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Sprint Bioscience affect the company?

A decrease in the liabilities of Sprint Bioscience can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Sprint Bioscience?

Some factors that can influence the liabilities of Sprint Bioscience include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Sprint Bioscience so important for investors?

The liabilities of Sprint Bioscience are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Sprint Bioscience take to modify the liabilities?

To change its liabilities, Sprint Bioscience can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Sprint Bioscience pay?

Over the past 12 months, Sprint Bioscience paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Sprint Bioscience is expected to pay a dividend of 0 SEK.

What is the dividend yield of Sprint Bioscience?

The current dividend yield of Sprint Bioscience is .

When does Sprint Bioscience pay dividends?

Sprint Bioscience pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Sprint Bioscience?

Sprint Bioscience paid dividends every year for the past 0 years.

What is the dividend of Sprint Bioscience?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Sprint Bioscience located?

Sprint Bioscience is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sprint Bioscience kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sprint Bioscience from 10/7/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 10/7/2024.

When did Sprint Bioscience pay the last dividend?

The last dividend was paid out on 10/7/2024.

What was the dividend of Sprint Bioscience in the year 2023?

In the year 2023, Sprint Bioscience distributed 0 SEK as dividends.

In which currency does Sprint Bioscience pay out the dividend?

The dividends of Sprint Bioscience are distributed in SEK.